OTCMKTS:DYAI

Dyadic International Stock News

Healthcare > Biotechnology

Buy DYAI

*Your capital is at risk

$1.05

-0.0200 (-1.87%)

At Close: Jul 31, 2026

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

08:30am, Tuesday, 28'th Jul 2026

JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approxim

Dyadic Announces Continued Listing on the Nasdaq Capital Market

07:30am, Friday, 24'th Jul 2026

JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing re

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

08:00am, Thursday, 16'th Jul 2026

JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinan

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential

07:25am, Tuesday, 07'th Jul 2026

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia

Dyadic Expands IP Protection and Business Development Activities in Japan

07:25am, Monday, 29'th Jun 2026

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on th

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

08:46am, Monday, 22'nd Jun 2026

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Appl

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

07:25am, Monday, 15'th Jun 2026

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on th

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

07:25am, Thursday, 28'th May 2026

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biot

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

04:05pm, Thursday, 21'st May 2026

JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a glob

Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET

03:45pm, Thursday, 21'st May 2026

Company invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ Company invites individu

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by